Agr2介导RNA聚合酶II核输入是野生型p53胰腺导管腺癌的特定靶点
研究在炎症加速的KrasG12D驱动小鼠模型中揭示,Agr2通过其C端核定位信号引导RNAPII核输入,削弱ADM病变中ATR依赖的p53激活,从而促进胰腺导管腺癌发生;遗传敲除Agr2可阻断化生向肿瘤转化。研究者开发六肽干扰Agr2-RNAPII复合物,在体内显著抑制PDAC起始,并使野生型p53的PDAC细胞和患者来源类器官对RNAPII抑制剂及一线化疗增敏。
要点
- Agr2在炎症和KrasG12D驱动的早期胰腺癌发生中上调,促进ADM向PanIN转化。
- Agr2通过C端核定位信号引导RNAPII核输入,削弱ATR依赖的p53激活。
- 六肽破坏Agr2-RNAPII复合物可抑制PDAC起始并增敏野生型p53肿瘤治疗。
核心结论
- Agr2是哺乳动物细胞中RNAPII核输入的新型衔接蛋白。
- Agr2依赖的RNAPII核输入是野生型p53背景下PDAC预防和治疗的可用药靶点。
研究设计与样本
- 使用炎症加速的KrasG12D驱动ADM和胰腺上皮内瘤变小鼠模型。
- 进行胰腺特异性Agr2敲除以评估其在胰腺癌发生中的作用。
- 开发脂质体负载的疏水性六肽以破坏Agr2-RNAPII复合物。
主要发现
- Agr2在炎症和KrasG12D驱动的早期胰腺癌发生中ADM向PanIN转变时上调。
- Agr2基因敲除特异性阻断化生向肿瘤转化过程。
- Agr2通过其C端核定位信号引导RNAPII核输入,削弱ADM病变中ATR依赖的p53激活。
- 六肽竞争性破坏Agr2-RNAPII复合物,导致早期肿瘤病变中RNAPII功能障碍并激活DNA损伤反应。
- 六肽在体内显著抑制PDAC起始,并使野生型p53的PDAC细胞和患者来源类器官对RNAPII抑制剂及一线化疗增敏。
临床怎么用
- 针对Agr2-RNAPII复合物的六肽可能用于野生型p53背景PDAC的预防和治疗。
- 六肽可增敏野生型p53 PDAC对RNAPII抑制剂和一线化疗的反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Promoted by pancreatitis, oncogenic KrasG12D triggers acinar cells' neoplastic transformation through acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia. Anterior gradient 2 (Agr2), a known inhibitor of p53, is detected at early stage of pancreatic ductal adenocarcinoma (PDAC) development. RNA polymerase II (RNAPII) is a key nuclear enzyme; regulation of its nuclear localization in mammalian cells represents a potential therapeutic target. METHODS: A mouse model of inflammation-accelerated KrasG12D-driven ADM and pancreatic intraepithelial neoplasia development was used. Pancreas-specific Agr2 ablation was performed to access its role in pancreatic carcinogenesis. Hydrophobic hexapeptides loaded in liposomes were developed to disrupt Agr2-RNAPII complex. RESULTS: We found that Agr2 is up-regulated in ADM-to-pancreatic intraepithelial neoplasia transition in inflammation and KrasG12D-driven early pancreatic carcinogenesis. Genetic ablation of Agr2 specifically blocks this metaplastic-to-neoplastic process. Mechanistically, Agr2 directs the nuclear import of RNAPII via its C-terminal nuclear localization signal, undermining the ATR-dependent p53 activation in ADM lesions. Because Agr2 binds to the largest subunit of RNAPII in a peptide motif-dependent manner, we developed a hexapeptide to interfere with the nuclear import of RNAPII by competitively disrupting the Agr2-RNAPII complex. This novel hexapeptide leads to dysfunction of RNAPII with concomitant activation of DNA damage response in early neoplastic lesions; hence, it dramatically compromises PDAC initiation in vivo. Moreover, the hexapeptide sensitizes PDAC cells and patient-derived organoids harboring wild-type p53 to RNAPII inhibitors and first-line chemotherapeutic agents in vivo. Of note, this therapeutic effect is efficient across various cancer types. CONCLUSIONS: Agr2 is identified as a novel adaptor protein for nuclear import of RNAPII in mammalian cells. Also, we provide genetic evidence defining Agr2-dependent nuclear import of RNAPII as a pharmaceutically accessible target for prevention and treatment in PDAC in the context of wild-type p53.
引用
- Zhang Z, Li H, Deng Y, et al. AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. Gastroenterology. 2021. PMID: 34303658. doi:10.1053/j.gastro.2021.07.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。